This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

CureVac (CVAC) Gets a Hold from Leerink Partners

Tipranks - Tipranks - Mon Mar 31, 2025

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on March 27. The company’s shares closed last Friday at $2.98.

Don't Miss Our End of Quarter Offers:

Foroohar covers the Healthcare sector, focusing on stocks such as Moderna, Alnylam Pharma, and BridgeBio Pharma. According to TipRanks, Foroohar has an average return of -13.1% and a 37.04% success rate on recommended stocks.

Currently, the analyst consensus on CureVac is a Hold with an average price target of $9.25.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $5.28 and a one-year low of $2.22. Currently, CureVac has an average volume of 825.9K.

Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CVAC in relation to earlier this year.

Read More on CVAC:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).